The estimated Net Worth of Gregory J. Herrema is at least $28.1 Миллион dollars as of 1 March 2019. Gregory Herrema owns over 3,299 units of Telesis Bio Inc stock worth over $50,080 and over the last 17 years Gregory sold TBIO stock worth over $28,083,467.
Gregory has made over 10 trades of the Telesis Bio Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Gregory sold 3,299 units of TBIO stock worth $867,802 on 1 March 2019.
The largest trade Gregory's ever made was selling 57,349 units of Telesis Bio Inc stock on 26 April 2011 worth over $3,297,568. On average, Gregory trades about 7,771 units every 80 days since 2008. As of 1 March 2019 Gregory still owns at least 29,459 units of Telesis Bio Inc stock.
You can see the complete history of Gregory Herrema stock trades at the bottom of the page.
Gregory's mailing address filed with the SEC is 168, Third Avenue, Waltham, Middlesex County, Massachusetts, 02451, United States.
Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk и Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Telesis Bio Inc executives and other stock owners filed with the SEC include: